Publications - ANRS CO22 HEPATHER

Late presentation for HCV care: time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort).

Santos M, Protopescu C, Delarocque-Astagneau E, Bourlière M, Petrov-Sanchez V, Di Beo V, Larrey D, Baudoin M, Dorival C, Bureau M, Fontaine H, Carrat F, Marcellin F, Pol S, Carrieri P, ANRS CO22 HEPATHER study group.

Liver International 2021 PMID: 34520614 DOI: 10.1111/liv.15056

Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors’ reply.
Pol S, Lusivika Nzinga C, Carrat F.

Aliment Pharmacol Ther. 2021 May;53(9):1050.doi: 10.1111/apt.16340.

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, De Ledinghen V, Zoulim F, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F.

JHEP Rep. 2021 Apr 24;3(4):100298.doi: 10.1016/j.jhepr.2021.100298. eCollection 2021 Aug.

Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study.
Lam L, Fontaine H, Bourlière M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D’Alteroch L, Portal I, Lapidus N, Pol S, Carrat F, ANRS/AFEF Hepather study group

Clin Res Hepatol Gastroenterol. 2021 Apr 27;45(5):101713.doi: 10.1016/j.clinre.2021.101713.

Aliment Pharmacol Ther. 2021 Mar;53(5):616-629.doi: 10.1111/apt.16197.

Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors’ reply.
Pol S, Lusivika-Nzinga C, Fontaine F, Carrat F, French ANRS CO22 Hepather cohort.

Aliment Pharmacol Ther. 2021 Mar;53(5):659.doi: 10.1111/apt.16251.

Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.
Tchadine D, Fontaine F, Baudoin M, Protopopescu C, Marcellin F, Dorival C, Simony M, Petrov-Sanchez V, Bourlière M, Delarocque-Astagneau E, Pol S, Carrat F, Carrieri P, ANRS CO22 Hepather study group.

Liver Int. 2021 Feb 16.doi: 10.1111/liv.14823

Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Lacombe JM, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, De Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L, ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups

J Hepatol. 2021 Jan;74(1):37-47. doi: 10.1016/j.jhep.2020.08.008. Epub 2020 Aug 14.

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A, Correas JM, Dorival C, Zoulim F, Tran A, Bourlière M, Calès P, Guyader G, Bronowicki JP, Larrey D, Hezode C, Loustaud-Ratti V, Gournay J, De Ledinghen V, Asselah T, Ganne N, Metivier S, Chazouillères O, Leroy V, Rosa I, Samuel D, Mathurin P, Cagnot C, Fontaine H, Carrat F, Pol S, AFEF ANRS study group

Clin Res Hepatol Gastroenterol. 2021 Jan;45(1):101459.doi: 10.1016/j.clinre.2020.04.022. Epub 2020 Jun 25.

Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
De Ledinghen V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, Larrey D, Metivier S, Tran A, Marcellin P, Samuel D, Chazouillères O, Chevaliez S, Dorival C, Fontaine H, Pawlotsky JM, Carrat F, Pol S; AFEF/ANRS Study Group.

J Viral Hepat. 2020 Oct;27(10):964-973. doi: 10.1111/jvh.13321. Epub 2020 May 21.

Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, Ouzan D, Papatheodoridis G, Ramji A, Borgia SM, Wedemeyer H, Losappio R, Pérez-Hernandez F, Wick N, Brown Jr RS, Lampertico P, Doucette K, Ntalla I, Ramroth H, Mertens M, Vanstraelen K, Turnes J

Liver Int. 2020 Aug;40(8):1841-1852. doi: 10.1111/liv.14537. Epub 2020 Jun 9.

Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
Barré T, Nishimwe ML, Protopopescu C, Marcellin F, Carrat F, Dorival C, Delarocque-Astagneau E, Larrey D, Bourlière M, Petrov-Sanchez V, Simony M, Pol S, Fontaine H, Carrieri P, ANRS/AFEF Hepather study group.

J Viral Hepat. 2020 Dec;27(12):1473-1483.doi: 10.1111/jvh.13380. Epub 2020 Sep 8.

Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes.
Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP.

Cancers (Basel). 2020 Nov 7;12(11):3295.doi: 10.3390/cancers12113295.

Genetic variation in IL-10 influences the progression of hepatitis B infection.
Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP.

Int J Infect Dis. 2020 Jul;96:260-265.doi: 10.1016/j.ijid.2020.04.079. Epub 2020 May 6.

The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C, Fontaine H, Dorival C, Simony M, Pol S, Carrat F; ANRS/AFEF Hepather study group.

J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13186.

Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy.
Pronier C, Fontaine H, Dorival C, Carrat F, Pol S, Thibault V; AFEF/ANRS Hepather study group.

J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13171.

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D’Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort.

Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S; ANRS/AFEF HEPATHER study group.

BMC Infect Dis. 2019 Apr 2;19(1):300. doi: 10.1186/s12879-019-3923-5.

Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection.
Feldman SF, Lapidus N, Dorival C, Diallo A, Amri I, Fontaine H, Pol S, Carrat F; ANRS/AFEF HEPATHER study group.

Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):797-805. doi: 10.1002/pds.4552. Epub 2018 May 11.

Letter: more studies are needed to elucidate the impact of HBV/HCV coinfection on cirrhosis and its consequences-Authors’ reply.
Pol S, Haour G, Fontaine H, Dorival C, Carrat F; on the behalf of the French ANRS C022 Hepather Cohort.

Aliment Pharmacol Ther. 2018 Feb;47(4):543-544. doi: 10.1111/apt.14476. No abstract available.

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.
Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, Capeau J, Carrieri P, Larrey D, Larsen C, Marcellin P, Pawlostky JM, Nahon P, Zoulim F, Cacoub P, de Ledinghen V, Mathurin P, Negro F, Pageaux GP, Yazdanpanah Y, Wittkop L, Zarski JP, Carrat F; French Anrs Co22 Hepather Cohort.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1054-1060. doi: 10.1111/apt.14352. Epub 2017 Oct 9.

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki JP, Ledinghen VD, Zoulim F, Tran A, Metivier S, Zarski JP, Samuel D, Guyader D, Marcellin P, Minello A, Alric L, Thabut D, Chazouilleres O, Riachi G, Bourcier V, Mathurin P, Loustaud-Ratti V, D’Alteroche L, Fouchard-Hubert I, Habersetzer F, Causse X, Geist C, Rosa I, Gournay J, Saillard E, Billaud E, Petrov-Sanchez V, Diallo A, Fontaine H, Carrat F; ANRS/AFEF HEPATHER study group.

J Hepatol. 2017 Jan;66(1):39-47. doi: 10.1016/j.jhep.2016.08.021. Epub 2016 Sep 10.

Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014.
Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C.

Euro Surveill. 2017 Jul 27;22(30). pii: 30582. doi: 10.2807/1560-7917.ES.2017.22.30.30582.

Reply to « A strong message is needed to address the issue of HCC recurrence after DAA therapy ».
Carrat F, Nahon P, Duclos-Vallée JC, Pageaux GP, Fontaine H, Pol S; ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts).

J Hepatol. 2016 Dec;65(6):1269-1270. doi: 10.1016/j.jhep.2016.07.030. Epub 2016 Jul 29.

Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr.

J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O.

Blood. 2016 Nov 24;128(21):2527-2532. Epub 2016 Sep 7.